To evaluate the efficacy and safety of antiretroviral simplification from a ritonavir-boosted protease inhibitor-based regimen [ protease inhibitor + RTV + two nucleos ( t ) ide reverse transcriptase inhibitors ( NRTIs ) ; 6 months of exposure prior to study entry with no prior treatment failure ] to the single-tablet regimen ( STR ) rilpivirine/emtricitabine/tenofovir disoproxil fumarate ( RPV/FTC/TDF ) in virologically suppressed , HIV-1-infected participants .